Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

Ding, Qingjie, Zhang, Zhuming, Liu, Jin-Jun, Jiang, Nan, Zhang, Jing, Ross, Tina M., Chu, Xin-Jie, Bartkovitz, David +9 more·2013·Journal of Medicinal Chemistry

DOI 10.1021/jm400487c

Cited by (617)

Items 401–500 of 617

Dipolarophile‐Steered Formal Stereodivergent Synthesis of 2,5‐cis/trans‐Pyrrolidines Based on Asymmetric 1,3‐Dipolar Cycloaddition of Imino Lactones
Shohei Furuya, Kenji Muroi, Kazuya Kanemoto, Shin‐ichi Fukuzawa · 2023 · Chemistry - A European Journal
Discovery of potent thiazolidin-4-one sulfone derivatives for inhibition of proliferation of osteosarcoma in vitro and in vivo
Xuwen Chen, Zhengli Luo, Zongjing Hu, Donghui Sun, Yingying He, Jiani Lu, Lili Chen, Shunying Liu · 2024 · European Journal of Medicinal Chemistry
A structure-based virtual screening identifies a novel MDM2 antagonist in the activation of the p53 signaling and inhibition of tumor growth
Qing-yong Hu, Lei Li, Yu-huang Li, Haibo Zhang, Tao Deng, Yang Liu, Feng-tian Li, Zhi‐Xiong Jim Xiao, Yang Cao · 2024 · Acta Pharmacologica Sinica
Molecular design and validation of halogen bonding orthogonal to hydrogen bonding in breast cancer MDM2–peptide complex
Anzhong Huang, Liang Yi Zhou, Dawei Zhang, Junliang Yao, Yong Zhang · 2016 · Journal of Molecular Graphics and Modelling
High-Throughput Drug Library Screening in Primary KMT2A-Rearranged Infant ALL Cells Favors the Identification of Drug Candidates That Activate P53 Signaling
Priscilla Wander, Susan T.C.J.M. Arentsen-Peters, Kirsten S. Vrenken, Sandra S. Pinhanços, Bianca Koopmans, M. Emmy M. Dolman, Luke Jones, Patricia Garrido Castro, Pauline Schneider, Mark JB Kerstjens et al. · 2022 · Biomedicines
Transcription Factors as Novel Therapeutic Targets and Drivers of Prostate Cancer Progression
Kangzhe Xie, Keely Tan, Matthew J. Naylor · 2022 · Frontiers in Oncology
Spirocyclic Scaffolds in Drug Discovery
Colin M. Tice, Ya‐Jun Zheng, Suresh B. Singh · 2016 · Elsevier eBooks
E3 Ubiquitin Ligases in Cancer and Their Pharmacological Targeting
Joseph Y. Ong, Jorge Z. Torres · 2019 · IntechOpen eBooks
The roles of ubiquitination in AML
Zhifeng Wei, Long Su, Sujun Gao · 2023 · Annals of Hematology
Genetic modeling of ELP1-associated Sonic hedgehog medulloblastoma identifies MDM2 as a selective therapeutic target
Shiekh Tanveer Ahmad, Yiran Li, Jesús García-López, Brian L. Gudenas, Jennifer L. Hadley, Leena Paul, Stephanie Wu, Alaa Refaat, Marija Kojic, Melissa Batts et al. · 2025 · Cancer Cell
Dual functionality of MDM2 in PROTACs expands the horizons of targeted protein degradation
Junyi Zhao, Hongzhen Chen, Chao Liang · 2025 · Biomarker Research
Synthesis and Antineoplastic Activity of a Dimer, Spiroindolinone Pyrrolidinecarboxamide
Jingyi Cui, Yujie Wang, Xiaoxin Li, Fei Xiao, Hongjun Ren, Meng Yin Wu · 2023 · Molecules
Synthesis and biological evaluation of 4-imidazolidinone–containing compounds as potent inhibitors of the MDM2/p53 interaction
Zhitong Lin, Chen Liu, Ziqin Yan, Jing Cheng, Xiancheng Wang, Feilong Zhou, Xilin Lyu, Shiyan Zhang, Daizhou Zhang, Xiangjing Meng et al. · 2024 · European Journal of Medicinal Chemistry
Pharmacological Inhibition of MDM2 Induces Apoptosis in p53-Mutated Triple-Negative Breast Cancer
Jasmin Linh On, Sahel Ghaderi, Carina Rittmann, G. Hoffmann, Franziska Gier, Vitalij Woloschin, Jia‐Wey Tu, Sanil Bhatia, Andrea Kulik, Dieter Niederacher et al. · 2025 · International Journal of Molecular Sciences
Up-Regulating Telomerase and Tumor Suppressors: Focusing on Anti-Aging Interventions at the Population Level
Fernando Pires Hartwig · 2014 · Aging and Disease
Pharmacological Activation of p53 during Human Monocyte to Macrophage Differentiation Attenuates Their Pro-Inflammatory Activation by TLR4, TLR7 and TLR8 Agonists
Dmitry Namgaladze, Bernhard Brüne · 2021 · Cancers
Novel MDM2 Inhibitor XR-2 Exerts Potent Anti-Tumor Efficacy and Overcomes Enzalutamide Resistance in Prostate Cancer
Meng Yin Wu, Jingyi Cui, Huimin Hou, Ying Li, Shengjie Liu, Li Wan, Lili Zhang, Wei Huang, Gaoyuan Sun, Jingchao Liu et al. · 2022 · Frontiers in Pharmacology
Therapeutic restoring p53 function with small molecule for oncogene-driven non-small cell lung cancer by targeting serine 392 phosphorylation
Liangping Li, Pingping Li, Xuesong Ma, Shulan Zeng, Yan Peng, Guohai Zhang · 2022 · Biochemical Pharmacology
Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution
Enrico Santinelli, Maria Rosaria Pascale, Zhuoer Xie, Talha Badar, Maximilian F. Stahl, Jan Philipp Bewersdorf, Carmelo Gurnari, Amer Methqal Zeidan · 2023 · Blood Reviews
Combination therapy with the type II anti-CD20 antibody obinutuzumab
Christian Klein, Marina Bacac, Pablo Umaña, Günter Fingerle‐Rowson · 2017 · Expert Opinion on Investigational Drugs
MDM2/P53 Inhibitors as Sensitizing Agents for Cancer Chemotherapy
Yan Yu Zhu, Herui Wang, Asha Thuraisamy · 2019 · Elsevier eBooks
Destruction and Construction: Application of Dearomatization Strategy in Aromatic Carbon–Nitrogen Bond Functionalization
Shuo‐En Wang, Linfei Wang, Qiuqin He, Renhua Fan · 2015 · Angewandte Chemie
The Development of New Spirooxindoles Targeting the p53–MDM2 Protein-Protein Interactions for Cancer Therapy
Bin Yu, Hong‐Min Liu · 2018 · Springer eBooks
A concise review on MDM2 inhibitors and recent progress in radiopharmaceutical development for imaging MDM2 expression in tumors with PET or SPECT
Atchimnaidu Siriki, Graham Ragland, Janardhan Vasireddy, Satish K. Chitneni · 2025 · Bioorganic & Medicinal Chemistry Letters
Targeting MDM2 for the development of a new cancer therapy: progress and challenges
Angelo Aguilar, Junius Eugene Thomas, Shaomeng Wang · 2023 · Medicinal Chemistry Research
Inhibition of protein-protein interactions using biodegradable depsipeptide nanoassemblies
Se-Hwan Choi, Hyun-seok Hwang, Seongryeong Han, Hohyeon Eom, Jun Shik Choi, Sang‐Hun Han, Dong‐Hyun Lee, Soo Yeon Lee, Heebeom Koo, Ho Jeong Kwon et al. · 2023 · Journal of Controlled Release
Inducing apoptosis in acute myeloid leukemia; mechanisms and limitations
Zahra Koolivand, Farbod Bahreini, Elham Rayzan, Nima Rezaei · 2024 · Heliyon
Design and synthetic approaches to thalidomide based small molecule degraders
Ajeet Kumar, Gulshan Kumar, Nidhi Kalia, Priya Ranjan Sahoo · 2025 · European Journal of Medicinal Chemistry
Revealing binding selectivity of ligands toward murine double minute 2 and murine double minute X based on molecular dynamics simulations and binding free energy calculations
Shuhua Shi, Kai Sui, Weizhe Liu, Yanzi Lei, Shaolong Zhang, Qinggang Zhang · 2019 · Journal of Biomolecular Structure and Dynamics
Fluorine-18 Labeling of the MDM2 Inhibitor RG7388 for PET Imaging: Chemistry and Preliminary Evaluation
Zhengyuan Zhou, Michael R. Zalutsky, Satish K. Chitneni · 2021 · Molecular Pharmaceutics
Targeting Protein Synthesis, Folding, and Degradation Pathways in Cancer
Elisa Pasqua, Birgit Wilding, Matthew D. Cheeseman, Keith Jones · 2017 · Elsevier eBooks
MDM2 and BCL-2: to p53 or not to p53?
Eunice S. Wang · 2023 · Blood
Predicting substrates for orphan solute carrier proteins using multi-omics datasets
Zhang, Y., Newstead, S., Sarkies, P. · 2025 · BMC Genomics
Thiazolidinones as Potential PGK1 Inhibitors for Treatment of Osteosarcoma Growth and Metastasis
Xuwen Chen, Meng Li, Zongjing Hu, Donghui Sun, Yikai Xu, Wenwen Dong, Tong Zhu, Weibin Zhang, Shunying Liu · 2025 · Journal of Medicinal Chemistry
MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms
Haifa Kathrin Al‐Ali, Sarah T. Heidel, Francesca Palandri, Florian H. Heidel · 2026 · Leukemia
RNA Aptamer-Based Approach to Inhibiting Split-GFP Reconstruction and the Loss of Inhibitory Activity Using Complementary RNA
Takuto Kamura, Yousuke Katsuda, Yusuke Fuchigami, Yua Itsuki, Yusuke Kitamura, Toshihiko Sakurai, Takeaki Ozawa, Toshihiro Ihara · 2023 · Bulletin of the Chemical Society of Japan
Hot-Spot-Guided Generative Deep Learning for Drug-Like PPI Inhibitor Design
Heqi Sun, Jiayi Li, Yufang Zhang, Shenggeng Lin, Junwei Chen, Hong Tan, Ruixuan Wang, Xueying Mao, Jianwei Zhao, Rongpei Li et al. · 2025 · Interdisciplinary Sciences Computational Life Sciences
Design of bifunctional molecules to accelerate post-translational modifications: achievements and challenges
Yuxuan Wang, Yanyi He, Qidong You, Lei Wang · 2024 · Drug Discovery Today
Highly Potent Clickable Probe for Cellular Imaging of MDM2 and Assessing Dynamic Responses to MDM2-p53 Inhibition
Honorine Lebraud, Richard A. Noble, Nicole Phillips, Keisha Heam, Juan Castro, Yan Zhao, David R. Newell, John Lunec, Stephen R. Wedge, Tom D. Heightman · 2018 · Bioconjugate Chemistry
Feasibility of Developing Radiotracers for MDM2: Synthesis and Preliminary Evaluation of an 18F-Labeled Analogue of the MDM2 Inhibitor SP-141
Satish K. Chitneni, Zhengyuan Zhou, Brian E. Watts, Michael R. Zalutsky · 2021 · Pharmaceuticals
Small-molecule MX-C2/3 suppresses non-small cell lung cancer progression via p53 activation
Liangping Li, Wenqing Du, Hui Wang, Yufei Zhao, Zetian Huang, Yan Peng, Shulan Zeng, Guohai Zhang · 2022 · Chemico-Biological Interactions
Focusing on shared subpockets – new developments in fragment-based drug discovery
Eman M. M. Abdelraheem, Carlos Jaime Camacho, Alexander S. S. Dömling · 2015 · Expert Opinion on Drug Discovery
The Clinical and Therapeutic Uses of MDM2 and PSMA and Their Potential Interaction in Aggressive Cancers
Robyn Bradbury, Wen G. Jiang, Yuxin Cui · 2015 · Biomarkers in Medicine
The lipid raft protein NTAL participates in AKT signaling in mantle cell lymphoma
Germano Aguiar Ferreira, Carolina Hassibe Thomé, Ana Maria Simão, Priscila Santos Scheucher, Cleide Lúcia Araújo Silva, Fernando Chahud, Pietro Ciancaglini, Andréia Machado Leopoldino, Eduardo Magalhães Rego, Vitor Marcel Faça et al. · 2019 · Leukemia & lymphoma/Leukemia and lymphoma
Discovery of SCY45, a Natural Small‐Molecule MDM2‐p53 Interaction Inhibitor
Haifeng Gong, Juan An, Qiuxia Dong, Jinxian Li, Wei Yang, Wei Sun, Zhanhai Su, Shoude Zhang · 2019 · Chemistry & Biodiversity
Enzymatic Desymmetrisation of Prochiral meso-1,2-Disubstituted-1,2-Diaminoethane for the Synthesis of Key Enantioenriched (−)-Nutlin-3 Precursor
Virginia Cristofori, Davide Illuminati, Chiara Bisquoli, Martina Catani, Greta Compagnin, Giulia Turrin, Claudio Trapella, Anna Fantinati · 2024 · Molecules
p53 prophylactic therapy for cancer prevention
Christian Krueger, Kanaga Sabapathy · 2025 · Cell Death and Differentiation
Zinc‐Catalyzed Enantioselective [3+2] Cycloaddition of Azomethine Ylides Using Planar Chiral [2.2]Paracyclophane‐Imidazoline N,O‐ligands
Sundaravel Vivek Kumar, Patrick J. Guiry · 2022 · Angewandte Chemie
Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia
Erhan Aptullahoğlu, Mohammed Howladar, Jonathan Peter Wallis, Helen J. Marr, Scott R Marshall, Julie A. E. Irving, Elaine Willmore, John Lunec · 2025 · Cancers
Targeting anti-apoptotic mechanisms in tumour cells: Strategies for enhancing Cancer therapy
Benu Chaudhary, Preeti Arya, Vikas Sharma, Parveen Kumar, Deepak Singla, Ajmer Singh Grewal · 2025 · Bioorganic Chemistry
A case report of giant retroperitoneal liposarcoma
Zicheng Bao, Nan Jia, Zhidong Zhang, Ping’an Ding, Qun Zhao, Xuefeng Zhao, Yong Li · 2025 · Medicine
Hijacking the MDM2 E3 Ligase with Novel BRD4‐Targeting Proteolysis‐Targeting Chimeras in Pancreatic Cancer Cells
Mihaela P. Ficu, Dan Niculescu‐Duvaz, Mohammed Aljarah, Christopher S. Kershaw, Caroline J. Springer · 2025 · ChemBioChem
Novel agents in follicular lymphoma: choosing the best target
Laurie Helen Sehn · 2016 · Hematology
Elucidation of Conformational Dynamics of MDM2 and Alterations Induced Upon Inhibitor Binding Using Elastic Network Simulations and Molecular Docking
Nigar Kantarci-Carsibasi · 2021 · Journal of Computational Biophysics and Chemistry
Accelerating Clinical Development of Idasanutlin through a Physiologically Based Pharmacokinetic Modeling Risk Assessment for CYP450 Isoenzyme-Related Drug–Drug Interactions
Kenichi Umehara, Yumi Cleary, Stephen M. Fowler, Neil John Parrott, Dietrich Tuerck · 2021 · Drug Metabolism and Disposition
Coccoquinones A and B, new anthraquinone derivatives produced by Staphylotrichum coccosporum PF1460
Daisuke Tatsuda, Masahide Amemiya, Ryûichi Sawa, Kengo Sumiyoshi, Takumi Watanabe, Isao Momose, Manabu Kawada, Akio Nomoto, Masakatsu Shibasaki · 2015 · The Journal of Antibiotics
Protein–Protein Interaction Inhibitors in Cancer
Ian Robert Hardcastle · 2016 · Elsevier eBooks
Targeting the Ubiquitin Proteasome System in Cancer
Nishi Kumari, Kwok Kin Lee, Sudhakar Jha · 2018 · InTech eBooks
Protein–Protein Interaction Inhibitors
Ian Robert Hardcastle · 2017 · Topics in medicinal chemistry
HDM2 and HDMX Proteins in Human Cancer
Lucia Hároníková, Bořivoj Vojtěšek · 2018 · Klinicka onkologie
GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers
Gaia Bianco, Mairene Coto‐Llerena, John Gallon, Stephanie Taha‐Mehlitz, Venkatesh Kancherla, Martina Konantz, Sumana Srivatsa, Hesam Montazeri, Federica Panebianco, Marta De Menna et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
Integrative machine learning approach for identification of new molecular scaffold and prediction of inhibition responses in cancer cells using multi-omics data
Aman Chandra Kaushik, Shubham Krushna Talware, Mohammad Imran Siddiqi · 2025 · Briefings in Functional Genomics
Chemical adaptation: bridging synthetic chemistry with drug development
Ke Ding, Yupeng Li, Yang Zhou, Weixue Huang · 2026 · Science China Life Sciences
Idasanutlin-ionizable lipid nanocomplex for enhanced solubility, stability, and anticancer activity in p53 sensitive lung cancer
Bhoomi Mukeshbhai Dholariya, Akanksha Patel, Rhema Khairnar, Henis J. Patel, Sunil Kumar, Ketan R. Patel · 2025 · Colloids and Surfaces B Biointerfaces
Differential Susceptibility of Ex Vivo Primary Glioblastoma Tumors to Oncolytic Effect of Modified Zika Virus
Gustavo Garcia, Nikhil Chakravarty, Sophia G. Paiola, Estrella Urena, Priya Gyani, Christopher Tse, Samuel William French, Moise Danielpour, Joshua J. Breunig, David A. Nathanson et al. · 2023 · Cells
The roles of ubiquitination‐mediated intrinsic apoptotic signalling in cancer therapy
Tiantian Che, Zhenghong Lin · 2022 · Clinical and Translational Discovery
Preclinical In Vitro Investigation of MDM2 Inhibition in Combination with Antiangiogenic Therapy for Breast Cancer Treatment
Ali Mohammed Alaseem, Khalid Alhazzani, Ahmed Z. Alanazi, Yasser A. Alqarni, Mohammad Algahtani, Abdullah S. Alhamed, Glowi A. Alasiri, Fahad T. Alotaibi, Talha Jawaid, Jehad A. Aldali · 2023 · Scientia Pharmaceutica
Insight into binding modes of p53 and inhibitors to MDM2 based on molecular dynamic simulations and principal component analysis
Wei-yuan Cheng, Zhiqiang Liang, Wei Wang, Changhong Yi, Hongyun Li, Shaolong Zhang, Qinggang Zhang · 2015 · Molecular Physics
In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of pyrazole-based small molecule inhibitors of Mdm2/4–p53 interaction
Susan M. Christner, Dana M. Clausen, Jan Hendrik Beumer, Robert A. Parise, Jianxia Guo, Yijun Huang, Alexander S. S. Dömling, Julie L. Eiseman · 2015 · Cancer Chemotherapy and Pharmacology
MetaReact: A Reaction-Aware Transformer for End-to-End Prediction of Drug Metabolism
Yitian Wang, Jingxin Rao, Wei Zhang, Yuqi Shi, Chuanlong Zeng, Rongrong Cui, Yinquan Wang, Jiacheng Xiong, Xutong Li, Mingyue Zheng · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
Dual inhibitor of MDM2 and NFAT1 for experimental therapy of breast cancer: in vitro and in vivo anticancer activities and newly discovered effects on cancer metabolic pathways
Wei Wang, Marlene Aguilar, Sayantap Datta, Abigail Alley, Meheret Tadesse, Xinshi Wang, Xia Gao, Ruiwen Zhang · 2025 · Frontiers in Pharmacology
p53 mutation-associated prognosis across cancer types underlines hematological malignancy as an applicable cancer type to p53-rescue therapy
Shujun Xiao, Jiaqi Wu, Kai Wei Tan, Sujiang Zhang, Yuting Dai, Jiarui Wu, Jiale Wu, Xinle Han, Derun Zheng, Xin Wang et al. · 2025 · Fundamental Research
Combining the NanaPPI Toolbox and AI-Driven Virtual Inhibitor Screening for the p53-MDM2 Interaction
Huijuan Liu, Hong Zhang, Saiyang Ding, Yue Xue, Xiangjun Du, Zhaoxue Han, Qianqian Li, Yi Qin Gao, Qin Peng · 2025 · Analytical Chemistry
Discovery of Furopyrimidine‐Pyrazole Hybrid Compounds Targeting p53‐MDM2 Interaction as Anticancer Agents
Mai A. Mansour, Ghaneya Sayed Hassan, Maiy Y. Jaballah, Rabah A.T. Serya, Necmi Dege, Onur Şahın, Marwa M. Sharaky, Xiaoliang Zhang, Ruixin Su, Kong De et al. · 2025 · Archiv der Pharmazie
Discovery of Novel Drug-Conjugate Molecule ZM484 with Dual p53-MDM2 and TOP1 Inhibition for the Treatment of Colorectal Cancer
Chuanhao Wang, Baobao Chen, Hang Yang, Chengyi Huang, Yanming Zhang, Jianyu Yan, Daozuan Zhang, Anhua Huang, Yuelin Wu, Junwu Zhu et al. · 2025 · Journal of Medicinal Chemistry
DNA ‐hypermethylated human gastric cancer circumvents apoptosis in the absence of TP53 mutation
Yasunobu Mano, Keisuke Matsusaka, M. Seki, Kazuko Kita, Masaki Fukuyo, Bahityar Rahmutulla, Genki Usui, Ryoji Fujiki, Masayuki Urabe, Hiroyuki Abé et al. · 2025 · The Journal of Pathology
Leveraging Targeted Protein Degradation for G Protein-Coupled Receptors: The Development of CCR2 Molecular Degraders
Khaled Essa, Natalia V. Ortiz Zacarı́as, Sascha Röth, Bo‐Tao Xin, Sabine de Winter, Cas van der Horst, Bente T.M. Bleijs, Richard A. de Heiden, Rodanthi Voulgaraki, Elsa Neubert et al. · 2025 · Journal of Medicinal Chemistry
A novel pyrrolidine-chalcone derivative exhibits synergistic anti-cervical cancer activity by dual-targeting MDM2-p53 axis and ferroptosis pathway
XinYi Deng, MOURBOUL Ablise, Hainimu Xiamuxi, Tong Yan, Madina Imam, Yu Wang, MingHui Zu, Wutiekuer Wumaier · 2026 · Frontiers in Pharmacology
Harnessing MDM2‐Mediated Targeted Degradation of Transcriptional and Epigenetic Machinery to Disrupt Oncogenic Addictions in Pediatric Sarcoma
Jiawei Zhou, Xian Guan, Nan Li, Ying Zhang, Long Xie, Xingze Huang, Zhipeng Zhu, Zhuolin Ren, Xiaoyan Yu, Hanjun Guo et al. · 2026 · Advanced Science
Open Access to High-Content Clonogenic Analysis
Fernanda Ricci, Aishwarya Subramanian, Mark R. Wade · 2014 · SLAS DISCOVERY
Drug Design Methods to Regulate Protein–Protein Interactions
Krishna Mohan Poluri, Khushboo Gulati, Deepak Kumar Tripathi, Nupur Nagar · 2023 · Springer eBooks
E3 ubiquitin ligases in nasopharyngeal carcinoma and implications for therapies
Zijian Zhou, Kaifeng Zheng, Shao Zhou, Youxiong Yang, Jun Chen, Xiaofeng Jin · 2023 · Journal of Molecular Medicine
Designer polyQ fusion proteins sequester USP7/HDM2 for modulating P53 functionality
Xiangle Zhang, Hong-Wei Yue, Yajun Liu, Jianyang Wang, Heng-Tong Duan, Yin-Hu Liu, Lei‐Lei Jiang, Hong‐Yu Hu · 2025 · iScience
Oxidative Stress-Responsive 1 Kinase Catalytic Activity Promotes Triple Negative Breast Cancer Oncogenic Potential
Azeza M. Fdel, Loren Waters, Ira Sharma, Samuel Jones, Julia M.W. Gee, John R. Atack, Sourav Banerjee, Youcef Mehellou · 2025 · ACS Pharmacology & Translational Science
Targeting Hdm2 and Hdm4 in Anticancer Drug Discovery: Implications for Checkpoint Inhibitor Immunotherapy
Monde McMillan Ntwasa · 2024 · Cells
Mechanism of Competition between Nutlin3 and p53 for Binding with Mdm2
Shuxia Liu, Shiwei Yan · 2017 · Chinese Physics Letters
The Diagnosis and Treatment of Retroperitoneal Mass
Ümit Gül · 2015 · Bulletin of Urooncology
An Application of Fit Quality to Screen MDM2/p53 Protein-Protein Interaction Inhibitors
Xin Xue, Gang Bao, Hai-Qing Zhang, Ning-Yi Zhao, Yuan Sun, Yue Zhang, Xiaolong Wang · 2018 · Molecules
Az akut mieloid leukémia kezelésének új lehetőségei: út a személyre szabott terápiás stratégiák felé
Zsolt Szakács, Hussain Alizadeh · 2022 · Hematológia–Transzfuziológia
Idasanutlin as a New Treatment Option in Improving the Therapeutic Odyssey of Relapsed/Refractory AML
Osman Corbali, Ahmet Emre Eşkazan · 2020 · Future Oncology
Identification of effective anti-osteosarcoma agents via screening of an in-house NQO1-targeted compound library
Xiang Li, Qijie Gong, Jianglin Yu, Jiaqi Liang, Rui Yao, Jian Zhou, Yaxin Chen, Zhijie Lei, Zhan Yu, Xiaojin Zhang et al. · 2025 · Bioorganic & Medicinal Chemistry
Synergistic MDM2-STAT3 Inhibition Demonstrates Strong Anti-Leukemic Efficacy in Acute Lymphoblastic Leukemia
Erhan Aptullahoğlu, Emrah Kaygusuz · 2025 · International Journal of Molecular Sciences
Asymmetric Induction of Sugar-Derived Dipole and Dipolarophile in 1,3-Dipolar Cycloadditions Leading to Pyrrolidines
Mariana Vardé, S. Suárez, Evangelina Repetto, Oscar J. Varela · 2025 · The Journal of Organic Chemistry
Enantioselective access to quaternary stereocenters of pyrrolidines via Rh-catalyzed intramolecular cyclization of 1,6-enynes
Runqi Hao, Fei Hou, Liqin Liu, Rao Wang, Yuan Tao, Zhenhua Jia, Fen‐Er Chen · 2025 · Organic & Biomolecular Chemistry
PROTAC-Mediated Targeted Degradation of MDM2 Induces Tumor-Suppressive Signaling in Osteosarcoma Cells
Yeongji Kim, J E Kim, Junwon Choi, Jinhyeong Kim, Soyeon Park, Wonji Choi, Hyun‐Ju An, Jinman Kim, Minsup Kim, Sujin Choi et al. · 2026 · Cells
Context matters in PROTAC design: navigating the trade-off between degradation and developability
Boxin Zhang, Yunfei Zhang, Bingxing Zhang, Jinrong Hu, Changhua Ke, Teng Wu, Meiyan Wei, Juan Xia, Mengzhou Wang, Qianqian Zhao et al. · 2026 · Journal of Enzyme Inhibition and Medicinal Chemistry
Nanotherapeutic formulations of enzyme inhibitors targeting cancer and neuroinflammation: An updated review
Yan Liu, Muthu Thiruvengadam, Rekha Arcot, Mohammad Ali Shariati, Zehra Edis, Ill-Min Chung, Shaozhuang Liu, Qi Xi · 2025 · Industrial Crops and Products
MDM2 and DNMT1 inhibitors induce neuroblastoma cell death through p53-dependent and independent pathways
Shyam Sundar Jaganathan, Umamaheswari Natarajan, Appu Rathinavelu · 2025 · Epigenomics
Discovery of N-pyridazin-3-piperidine derivatives acting as p53 activators against breast cancer: In vitro and in silico evaluations
Aoxuan Zhang, Bowen Tang, Siyu Zhou, Chaoyang Sui, Shilin He, Yingying Liu, Mingdong Li, Yuqing Qian · 2025 · Bioorganic & Medicinal Chemistry
Multi-Step Synthesis of Chimeric Nutlin–DCA Compounds Targeting Dual Pathways for Treatment of Cancer
Davide Illuminati, Rebecca Foschi, Paolo Marchetti, Vinicio Zanirato, Anna Fantinati, Claudio Trapella, Rebecca Voltan, Virginia Cristofori · 2025 · Molecules